Anti-Infective strategies of the future: Is there room for species-specific antibacterial agents?

Current Pharmaceutical Design

Volumn 16, Issue 5, 2010, Pages 555-566

  Then, Rudolf L ^a   Sahl, Hans Georg ^b  

^a Immunology and Parasitology ^*  (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Antibiotics; Infectious diseases; Narrow spectrum antibiotics; Pathogen specific therapy

Indexed keywords

2 ARYLALKYLGUANIDINO 4 FURYLTHIAZOLE; ACTINOPYRONE; AFN 1252; ANTIINFECTIVE AGENT; API 1252; AUREOTHAN; BACIMETHRIN; BAS 118; BENZAMIDE; BENZA[A]ANTHRACHINONE; BENZIMIDAZOLE DERIVATIVE; BENZOPHENANTHROLINE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; FINAFLOXACIN; GAMMA PYRONES N ACETYL AUREOTHAMINE; INDOLMYCIN; LUMINAMICIN; MUREIDOMYCIN A; MUREIDOMYCIN B; MUREIDOMYCIN C; MUREIDOMYCIN D; MUT 056399; OXODIAZOLOPYRAZINE; PHTHALIDE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PYLORICIDIN; PYRAZOLE; PYRAZOLOPYRIMIDINEDIONE; PYRIDODIAZEPINE AMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAK 083; THIADIAZOLIDINEDIONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 181 741;

ACINETOBACTER; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBODY SPECIFICITY; ANTIMICROBIAL THERAPY; BACTERIAL METABOLISM; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BINDING AFFINITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG ACTIVATION; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENTEROBACTERIACEAE; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HAEMOPHILUS INFLUENZAE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RADIOIMMUNOTHERAPY; REVIEW; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 77949479807     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790361407     Document Type: Review

References (100)

1. Pachòn J, Vila J. Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Investig Drugs 2009; 10: 150-6.
2. Shlaes DM. The abandonment of antibacterials: why and wherefore? Curr Opin Pharmacol 2003; 3: 470-3.
3. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev Drug Disc 2007; 6: 29-40.
4. Lange RP, Locher HH, Wyss PC, Then RL. The targets of currently used antibacterial agents: lessons for drug design. Curr Pharm Des 2007; 13: 3140-54.
5. Brötz-Oesterhelt H, Brunner NA. How many modes of action should an antibiotic have? Curr Opin Pharmacol 2008; 8: 564-73.
6. Casadevall A. The third age of antimicrobial therapy. Clin Infect Dis 2006; 42: 1414-16.
7. Casadevall A. The case for pathogen-specific therapy. Expert Opin Pharmacother 2009; 10: 1-5
8. Pirofski LA, Casadevall A. Immunomodulators as an antimicrobial tool. Curr Opinion Microbiol 2006; 9: 489-95.
9. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends - is a paradigm change coming soon? Methods Mol Biol 2009; 525: 1-27.
10. Dadachova E, Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Expert Opinion Drug Deliv 2005; 2: 1075-84.
11. Bryan RA, Huang X, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. Radiofungicidal effects of external gamma radiation and antibody-targeted β and α radiation on Cryptococcus neoformans. Antimicrob Agents Chemother 2008; 52: 2232-5.
12. Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-7.
13. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, Thompson A, et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 2007; 25: 465-72.
14. Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 2008; 12: 400-8.
15. st century [in French]. Med Mal Infect 2008; 38: 421-5.
16. Deresinski S. Bacteriophage therapy: exploiting smaller fleas. Clin Infect Dis 2009; 48: 1096-101.
17. O'Flaherty S, Ross RP, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 2009; 33: 801-19.
18. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649-59.
19. Cairns BJ, Payne RJH. Bacteriophage therapy and the mutant selection window. Antimicrob Agents Chemother 2008; 52: 4344-50.
20. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008; 11: 393-400.
21. Turner PR, Denny WA. The genome as a drug target: sequence specific minor groove binding ligands. Curr Drug Targets 2000; 1: 1-14.
22. Carthew RW. Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
23. vanMil A, Doevendans PA, Sluijter JP. The potential of modulating small RNA activity in vivo. Mini Rev Med Chem 2009; 9: 235-48.
24. Van Belkum A. Molecular diagnostics in medical microbiology: yesterday, today and tomorrow. Curr Opin Pharmacol 2003; 3: 497-501.
25. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
26. Cole ST, Alzari PM. TB- a new target, a new drug. Science 2005; 307: 214-5.
27. Kompis IM, Islam K, Then RL. DNA and RNA synthesis: Antifolates. Chem Rev 2005; 105: 593-620.
28. Wilson DN, Harms JM, Nierhaus KH, Schlünzen F, Fucini P. Species-specific antibiotic-ribosome interactions: implications for drug development. Biol Chem 2005; 386: 1239-52.
29. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetic by pyrazinoic acid. J Antimicrob Chemother 2003; 52: 790-5.
30. Pal D, Banerjee S, Cui J, Schwartz A, Ghosh SK, Samuelson J. Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother 2009; 53: 458-64.
31. Nottebrock H, Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol 1977; 26: 2175-9.
32. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46: 584-93.
33. Saito H, Tomioka H, Ohkido S. Further studies on thymidine kinase: distribution pattern of the enzyme in bacteria. J Gen Microbiol 1985; 131: 3091-8.
34. Shibl AM, Ishag AH, Durgham SM. Comparative in vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria. Chemotherapy 1989; 35 (Suppl 1): 72-6.
35. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921-8.
36. Falagas ME, Agrafiotis M, Athanassa Z, Siempos II. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev Anti Infect Ther 2008; 6: 447-52.
37. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. Inhaled colistin as monotherapy for multi-drugresistant gram-negative nosocomial pneumonia: a case series. Respir Med 2009; 103: 707-13.
38. Marklein G, Josten M, Klanke U, Müller E, Horré R, Maier T, et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol 2009; 47: 2912-7.
39. Warren JR, Marshall BJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 16: 1311-5.
40. The European Helicobacter Pylori Study group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
41. Nakao M, Miyagawa KI, NakanoY, Sakane T, Tada M, Nishimura O, et al. Pyloricidins, novel anti-Helicobacter pylori antibiotics produced by Bacillus sp. I. Taxonomy, fermentation and biological activity. J Antibiotics 2001; 54: 926-33.
42. Nagano Y, Ikedo K, Fujishima A, Izawa M, Tsubotani S, Nishimura O, et al. Pyloricidins, novel anti-Helicobacter pylori antibiotics produced by Bacillus sp. II Isolation and structure elucidation. J Antibiotics 2001; 54: 934-47.
43. Kanamura T, Nakano Y, Toyoda Y, Miyagawa KI, Tada M, Kaisho T, et al. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother 2001; 45: 2455-9.
44. Basarab GS, Hill PJ, Rastagar A, Webborn PJH. Design of Helicobacter pylori glutamate racemase inhibitors as selective antibacterial agents: a novel pro-drug-approach to increase exposure. Bioorg Med Chem Lett 2008; 18: 4716-22.
45. Geng B, Basarab G, Comita-Prevoir J, Gowravaram M, Hill P, Kiely A, et al. Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): Pyridodiazepine amines. Bioorg Med Chem Lett 2009; 19: 930-6.
46. Sjöström JE, Kühler T, Larsson H. Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother 1997; 41: 1797-801.
47. Kühler TC, Swanson M, Christenson B, Klintenberg AC, Lamm B, Fägerhag J, et al. Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, part I. J Med Chem 2002; 45: 4282-99.
48. Carcanague D, Shue YK, Wuonola MA, Uria-Nickelsen M, Joubran C, Abedi JK, et al. Novel structures derived from 2-[[(2-pyridyl)methyl]thio]-1H- benzimidazole as anti-Helicobacter pylori agents, part 2. J Med Chem 2002; 45: 4300-9.
49. Katsura Y, Tomishi T, Inoue Y, Sakane K, Matsumoto Y, Ishikawa H, et al. Anti-Helicobacter pylori agents. 1. 2-(alkylguanidino)-4- furylthiazoles and related compounds. J Med Chem 1997; 40: 2462-5.
50. Katsura Y, Nishino S, Tomishi T, Inoue Y, Sakane K, Matsumoto Y, et al. Anti-Helicobacter pylori agents. 2. Structure activity relationships in a new series of 2-alkylguanidino-4-furylthiazoles. Bioorg Med Chem Lett 1998; 8: 1307-12.
51. Katsura Y, Nishino S, Ohno M, Sakane K, Matsumoto Y, Morinaga C, et al. Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4- furylthiazoles. J Med Chem 1999; 42: 2920-6.
52. Katsura Y, Tomishi T, Inoue Y, Sakane K, Matsumoto Y. Moringa C, et al. Anti-Helicobacter pylori agents. 4. 2-(substituted guanidine)-4-phenylthiazoles and some structurally rigid derivatives. J Med Chem 2000; 43: 3315-21.
53. Katsura Y, Nishino S, Inoue Y, Sakane K, Matsumoto Y, Moringa C, et al. Anti-Helicobacetr pylori agents. 5. 2-(substituted guanidine)-4-arylthiazoles and aryloxazole analogues. J Med Chem 2002; 45: 143-50.
54. Dekker KA, Inagaki T, Gootz TD, Kaneda K, Nomura E, Sakakibara T, et al. CJ-12,954 and its congeners, new anti-Helicobacter pylori compounds produced by Phanerochaete velutina. J Antibiotics 1997; 50: 833-9.
55. Dekker KA, Inagaki T, Gootz TD, Huang LH, Kojima Y, Kohlbrenner WE, et al. New quinolone compounds from Pseudonocardia sp. with selective and potent anti - Helicobacter pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activities. J Antibiotics 1998; 51: 145-52.
56. Sugimori G, Masui M, Nishida K, Hasegawa Y, Kobayashi N. Compounds against Helicobacter Activity. Shionogi & Co.; Ltd. Patent WO 03095453, 08.05.2003
57. Taniguchi M, Watanabe M, Nagai K, Suzumura KI, Suzuki KI, Tanaka A. γ-pyrone compounds with selective and potent anti-Helicobacter pylori activity. J Antibiotics 2000; 53: 844-7.
58. Taniguchi M, Nagai K, Watanabe M, Nimura N, Suzuki KI, Tanaka A. YM-181 741, a novel benz[α]anthraquinone antibiotic with anti-Helicobacter pylori activity from Streptomyces sp. J Antibiotics 2002; 55: 30-5.
59. Kobayashi I, Muraoka H, Hasegawa M, Saika T, Nishida M, Kawamura M, et al. In vitro anti-Helicobacter pylori activity of BAS-118, a new benzamide derivative. J Antimicrob Chemother 2002; 50: 129-32.
60. deJonge BLM, Kutschke A, Uria-Nickelsen M, Kamp HD, Mills SD. Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI). Antimicrob Agents Chemother 2009; 53: 3331-6.
61. Isono F, Kodama K, Inukai M. Susceptibility of Pseudomonas species to the novel antibiotics mureidomycins. Antimicrob Agents Chemother 1992; 36: 1024-7.
62. Inukai M, Isono F, Takatsuki A. Selective inhibition of the bacterial translocase reaction in peptidoglycan synthesis by mureidomycins. Antimicrob Agents Chemother 1993; 37: 980-3.
63. Gotoh N, Murata T, Ozaki T, Kimura T, Kondo A, Nishino T. Intrinsic resistance of Escherichia coli to mureidomycin A and C due to expression of the multidrug efflux system AcrAB-TolC: comparison with the efflux systems of mureidomycin-susceptible Pseudomonas aeruginosa. J Infect Chemother 2003; 9: 101-3.
64. Fernandes PB, Swanson RN, Hardy DJ, Hanson CW, Coen L, Rasmussen RR, et al. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III Microbiologic profile. J Antibiotics 1989; 42: 521-6.
65. Bugg TD, Lloyd AJ, Roper DI. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord Drug Targets 2006; 6: 85-106.
66. Boojamra CG, Lemoine RC, Blais J, Vernier NG, Stein KA, Magon A, et al. Synthetic dihydropacidamycin antibiotics: a modified spectrum of activity for the pacidamycin class. Bioorg Med Chem Lett 2003; 13: 3305-9.
67. Grüschow S, Rackham EJ, Elkins B, Newill PL, Hill LM, Goss RJ. New pacidamycin antibiotics through precursor-directed biosynthesis. ChemBioChem 2009; 26: 355-60.
68. Obrecht D, Robinson JA, Bernardini F, Bisang C, DeMarco SJ, Moehle K, et al. Recent progress in the discovery of macrocyclic compounds as potential anti-infective therapeutics. Curr Med Chem 2009; 16: 42-65.
69. Lu H, Tonge PJ. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res 2008; 41: 11-20.
70. Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, et al In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 2007; 51: 1580-81.
71. Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob Agents Chemother 2009; 53: 3544-8.
72. Tomoda H, Iwata R, Takahashi Y, Iwai Y, Ōiwa R, Ōmura S. Lustromycin, a new antibiotic produced by Streptomyces sp. J Antibiotics 1986; 39: 1205-10.
73. Rasmussen RR, Scherr MH, Whittern DN, Buko AM. McAlpine JB. Coloradocin, an antibiotic from a new Actinoplanes II. Identity with luminacin and elucidation of structure. J Antibiotics 1987; 40: 1383-93.
74. Jackson M, Karwowski JP, Theriault RJ, Fernandes PB, Semon RC, Kohl WL. Coloradocin, an antibiotic from a new Actinoplanes I. Taxonomy, fermentation and biological properties. J Antibiotics 1987; 40: 1375-82.
75. Beebe X, Nilius AM, Merta PJ, Soni NB, Bui MH, Wagner R, et al. Synthesis and SAR evaluation of oxadiazolopyrazines as selective Haemophilus influenzae antibacterial agents. Bioorg Med Chem Lett 2003;13: 3133-6.
76. Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem 2004; 279: 33035-8.
77. Nørager S, Jensen KF, Björnberg O, Larsen S. E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure 2002; 10: 1211-23.
78. Copeland RA, Marcinkeviciene J, Haque TS, Kopcho LM, Jiang W, Wang K, et al. Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis. J Biol Chem 2000; 275: 33373-8.
79. Haque TS, Tadesse S, Marcinkeviciene J, Rogers MJ, Sizemore C, Kopcho LM, et al. Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase. J Med Chem 2002; 45: 4669-78.
80. Marcinkeviciene J, Rogers MJ, Kopcho L, Jiang W, Wang K, Murphy DJ, et al. Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones. Biochem Pharmacol 2000; 60: 339-42.
81. Heikkilä T, Thirumalairajan S, Davies M, Parsons MR, McConkey AG, Fishwick CWG, et al. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett 2006; 16: 88-92.
82. Phillips MA, Gujjar R, Malmquist NA, White J, Mazouni F, Baldwin J, et al. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. J Med Chem 2008; 51: 3649-53.
83. Patel V, Booker M, Kramer M, Ross L, Celatka CA, Kennedy LM, et al. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 2008; 283: 35078-85.
84. Gustafson G, Davis G, Waldron C, Smith A, Henry M. Identification of a new antifungal target site through a dual biochemical and molecular-genetics approach. Curr Genet 1996; 30: 159-65.
85. Arakaki TL, Buckner FS, Gillespie JR, Malmquist NA, Phillips MA, Kalyuzhniy O, et al. Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol 2008; 68: 37-50.
86. Settembre E, Begley TP, Ealick SE. Structural biology of enzymes of the thiamin biosynthesis pathway. Curr Opin Struct Biol 2003; 13: 739-47.
87. Drautz H, Messerer W, Zähner H. Metabolic products of microorganisms. 239. Bacimethrin isolated from Streptomyces albus; identification, derivatives, synthesis and biological properties. J Antibiotics 1987; 40: 1431-9.
88. Reddick JJ, Saha S, Lee J, Melnick JS, Perkins J, Begley TP. The mechanism of action of bacimethrin, a naturally occurring thiamin antimetabolite. Bioorg Med Chem Lett 2001; 11: 2245-8.
89. Webb E, Claas K, Downs D. thiBPQ encodes an ABC transporter required for transport of thiamine pyrophosphate in Salmonella typhimurium. J Biol Chem 1998; 273: 8946-50.
90. Iwashima A, Nose Y. Inhibition of thiamine transport by chloroethylthiamine in Escherichia coli. J Bacteriol 1972; 112: 1438-40.
91. Wyss O. Antibacterial action of a pyridine analogue of thiamine. J Bacteriol 1943; 46: 483-4.
92. Sudarsan N, Cohen-Chalamish S, Nakamura S, Emilsson GM, Breaker RR. Thiamine pyrophosphate Riboswitches are targets for the antimicrobial compound pyrithiamine. Chem Biol 2005; 12: 1325-35.
93. Blount KF, Breaker RR. Riboswitches as antibacterial drug targets. Nat Biotechnol 2006; 24: 1558-64.
94. Rodionov DA, Vitreschak AG, Mironov AA, Gelfand MS. Comparartive genomics of thiamine biosynthesis in prokaryotes. New genes and regulatory mechanisms. J Biol Chem 2002; 277: 48949-59.
95. Zilles J, Croal LR, Downs DM. Action of the thiamine antagonist bacimethrin on thiamine biosynthesis. J Bacteriol 2000; 182: 5606-10.
96. Lowe G, Potter BVL. Bacteriostatic activity of fluoro-analogues of 5-(2-hydroxyethyl)-4-methylthiazole, a metabolic intermediate in the biosynthesis of thiamine. J Chem Soc Perkin Trans1 1980; 2026-8.
97. Morgunova E, Illarionov B, Sambaiah T, Haase I, Bacher A, Cushman M, et al. Structural and thermodynamic insights into the binding mode of five novel inhibitors of lumazine synthase from Mycobacterium tuberculosis. FEBS J 2006; 273: 4790-804.
98. Davtyan TK, Mkhitaryan LM, Gabrielyan ES. Design of iodinelithium-alpha- dextrin liquid crystal with potent antimicrobial and anti-inflammatory properties. Curr Pharm Des 2009; 15(11): 1172-86.
99. Hatakka K, Saxelin M. Probiotics in intestinal and non-intestinal infectious diseases - clinical evidence. Curr Pharm Des 2008; 14(14): 1351-67.
100. Vinsova J, Vavrikova E. Recent advances in drugs and prodrugs design of chitosan. Curr Pharm Des 2008; 14(13): 1311-26.